For glioblastoma (GBM), a blood-brain barrier-penetrating delivery system was developed using Angiopep-2/TAT peptide-modified extracellular vesicles (EVs) to transport Cas9/sgRNA complexes targeting glutathione synthetase (GSS). The gene discussed is GSS; the disease is glioblastoma.